These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Inhibition of prostaglandin induced uterine activity in the second trimester of pregnancy by beta-mimetic adrenergic agents.
    Author: Lindmark G, Melander S, Nilsson BA, Zador G.
    Journal: Prostaglandins; 1973 Apr; 3(4):481-9. PubMed ID: 4147100.
    Abstract:
    Clinical research was undertaken to study the effect of 2 beta-mimetic adrenergic agents, orciprenaline and ritodrine, on uterine activity produced by administration of PGF2alpha (prostaglandin) in the 2nd trimester of pregnancy. Subjects were 8 women admitted to the University Hospital in Uppsala, Sweden, for a therapeutic abortion in the 16h-24th week of pregnancy. 4 were given orciprenaline extraamniotically and 4 were given ritodrine intraamniotically. Infusion of both the substances caused a decline in the frequency and intensity of uterine activity, which had previously been induced by administration of PGF2alpha. For both drugs, the reduction in uterine activity was dose-related. Both drugs caused an increased maternal heart rate. Ritodrine also produced a rise in systolic and a fall in diastolic pressure. No other side effects were observed. Discontinuation of the drug infusion caused uterine activity to increase. Results of the study demonstrate that beta-mimetic adrenergic agents are capable of inhibiting PG effects on uterine activity. To achieve a significant reduction, however, the dose must be large enough to cause tachycardia and palpitation, side effects tolerated well by the patients.
    [Abstract] [Full Text] [Related] [New Search]